An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.

Autor: Rodríguez M; Pathology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain.; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain., Alonso-Alonso R; Pathology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain.; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain., Fernández-Miranda I; Lymphoma Research Group IIS Puerta de Hierro-Segovia de Arana (IDIPHISA) Madrid Spain., Mondéjar R; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain.; UGC Laboratorios Hospital Universitario Puerto Real Cádiz Spain., Cereceda L; Pathology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain.; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain., Tráscasa Á; Pathology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain., Antonio-Da Conceiçao A; Pathology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain., Borregón J; Pathology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain., Gato L; Pathology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain., Tomás-Roca L; Pathology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain., Bárcena C; Pathology Department Hospital Universitario Doce de Octubre Madrid Spain., Iglesias B; Pathology Department Hospital Álvaro Cunqueiro Vigo Spain., Climent F; Pathology Department Hospital Universitari de Bellvitge L'Hospitalet de Llobregat Barcelona Spain., González-Barca E; Haematology Department Institut Català d'Oncologia Hospital Duran i Reynals L'Hospitalet de Llobregat Barcelona Spain., Camacho FI; Pathology Department Hospital Universitario de Getafe Madrid Spain., Mayordomo É; Pathology Department Hospital Universitario y Politécnico La Fe Valencia Spain., Olmedilla G; Pathology Department Hospital Universitario La Paz Madrid Spain., Gómez-Prieto P; Haematology Department Hospital Universitario La Paz Madrid Spain., Castro Y; Pathology Department Hospital Universitario Príncipe de Asturias Madrid Spain., Serrano-López J; Experimental Hematology Laboratory IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain., Sánchez-García J; Haematology Department Hospital Universitario Reina Sofia Maimonides Biomedical Research Institute IMIBIC University of Córdoba Córdoba Spain., Montes-Moreno S; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain.; Pathology Department Hospital Universitario Marqués de Valdecilla Santander Spain., García-Cosío M; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain.; Pathology Department Hospital Universitario Ramón y Cajal Madrid Spain., Martín-Acosta P; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain.; Pathology Department Hospital Universitario Puerta de Hierro Madrid Spain., García JF; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain.; Pathology Department MD Anderson Cancer Center Madrid Spain., Planelles M; Pathology Department Hospital General Universitario de Alicante Alicante Spain., Quero C; Clinical Oncology Department Hospital General Universitario Virgen de la Victoria Complejo Hospital Costa del Sol Marbella (Málaga) Spain., Provencio M; Clinical Oncology Department IIS Puerta de Hierro-Segovia de Arana (IDIPHISA) Madrid Spain., Mahíllo-Fernández I; Department of Epidemiology IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain., Rodríguez-Pinilla SM; Pathology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain.; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain., Derenzini E; Divisions of Haemato-Oncology and Haematopathology IEO European Institute of Oncology IRCCS Milan Italy., Pileri S; Divisions of Haemato-Oncology and Haematopathology IEO European Institute of Oncology IRCCS Milan Italy., Sánchez-Beato M; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain.; Haematology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain., Córdoba R; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain.; Haematology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain., Piris MA; Pathology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain.; Center for Biomedical Network Research on Cancer (CIBERONC) ISCIII Madrid Spain.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2022 May 03; Vol. 3 (3), pp. 722-733. Date of Electronic Publication: 2022 May 03 (Print Publication: 2022).
DOI: 10.1002/jha2.457
Abstrakt: Diffuse large B-cell lymphoma (DLBCL), the most frequent non-Hodgkin's lymphoma subtype, is characterized by strong biological, morphological, and clinical heterogeneity, but patients are treated with immunochemotherapy in a relatively homogeneous way. Here, we have used a customized NanoString platform to analyze a series of 197 homogeneously treated DLBCL cases. The platform includes the most relevant genes or signatures known to be useful for predicting response to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in DLBCL cases. We generated a risk score that combines the International Prognostic Index with cell of origin and double expression of MYC/BCL2 , and stratified the series into three groups, yielding hazard ratios from 0.15 to 5.49 for overall survival, and from 0.17 to 5.04 for progression-free survival. Group differences were highly significant ( p  < 0.0001), and the scoring system was applicable to younger patients (<60 years of age) and patients with advanced or localized stages of the disease. Results were validated in an independent dataset from 166 DLBCL patients treated in two distinct clinical trials. This risk score combines clinical and biological data in a model that can be used to integrate biological variables into the prognostic models for DLBCL cases.
Competing Interests: M.A.P. declares having received lecture fees and advisory board fees from Millennium/Takeda, Jansen, NanoString, Kyowa Kirin, Gilead, and Celgene.The authors declare that they have no significant relationships with, or financial interests, in any commercial companies pertaining to this article.
(© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: